Kalohexis Files Confidential IPO to Fund Obesity and Cachexia Therapies
Kalohexis, a clinical-stage biotech focused on metabolic health, has confidentially filed for an initial public offering (IPO) with the SEC. The company aims to advance its pipeline of peptide-based therapeutics targeting obesity and cancer cachexia.